The relevance of the association between inflammation and atrial fibrillation

European Journal of Clinical Investigation

Volumn 43, Issue 4, 2013, Pages 324-331

  Alegret, Josep M ^a   Aragonès, Gerard ^a,b   Elosua, Roberto ^c   Beltrán Debón, Raúl ^a,b   Hernández Aguilera, Anna ^b   Romero Menor, César ^d   Camps, Jordi ^b   Joven, Jorge ^b  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

C reactive protein; Chemoattractants; Paroxysmal; Permanent; Rhythm control

Indexed keywords

C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ATRIAL FIBRILLATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84875379006     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12047     Document Type: Article

References (38)

1. Chinitz JS, Castellano JM, Kovacic JC, Fuster V. Atrial fibrillation, stroke, and quality of life. Ann N Y Acad Sci 2012;1254:140-50.
2. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4.
3. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 2011;17:556-63.
4. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007;50:2021-8.
5. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA et al. C-Reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91.
6. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
7. Wazni O, Martin DO, Marrouche NF, Shaaraoui M, Chung MK, Almahameed S et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005;91:1303-5.
8. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010;7:438-44.
9. Hammwöhner M, Ittenson A, Dierkes J, Bukowska A, Klein HU, Lendeckel U et al. Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Exp Biol Med 2007;232:581-9.
10. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.
11. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
12. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011;13:610-25.
13. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008;52:306-13.
14. Coll B, Alonso-Villaverde C, Joven J. Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker? Clin Chim Acta 2007;383:21-9.
15. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004;110:2204-9.
16. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42.
17. Zacho J, Tybajaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C - reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
18. http://www.bancoadn.org/.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9.
20. Alegret JM, Viñolas X, Sagristá J, Hernandez-Madrid A, Pérez L, Sabaté X et al. Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation. Europace 2007;9:942-6.
21. Alegret JM, Vinolas X, Romero-Menor C, Pons S, Villuendas R, Calvo N et al. Trends in the use of electrical cardioversion for atrial fibrillation: influence of major trials and guidelines on clinical practice. BMC Cardiovasc Disord 2012;12:42.
22. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J 2006;27:1979-2030.
23. Lévy S. Classification system of atrial fibrillation. Curr Opin Cardiol 2000;15:54-7.
24. Virgos C, Martorell L, Valero J, Figuera L, Civeira F, Joven J et al. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 2001;49:65-71.
25. Simó JM, Castellano I, Ferré N, Joven J, Camps J. Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clin Chem 1998;44:1233-41.
26. Matas C, Cabré M, La Ville A, Prats E, Joven J, Turner PR et al. Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. Clin Chem 1994;40:404-6.
27. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004;43:2075-82.
28. De Gennaro L, Brunetti ND, Montrone D, De Rosa F, Cuculo A, Di Biase M. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur J Clin Invest 2012;42:371-5.
29. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012;61:416-26.
30. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jönsson A, Säfström K et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008;10:848-53.
31. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47, 000 individuals from the general population. J Am Coll Cardiol 2010;56:789-95.
32. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005;112:1113-20.
33. Alonso-Villaverde C, Aragonès G, Beltrán-Debón R, Fernández-Sender L, Rull A, Rodríguez-Sanabria F et al. Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: the role of CCL2 genetic variants. Cytokine 2010;51:251-8.
34. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-reactive protein in lone atrial fibrillation. Am J Cardiol 2006;97:1346-50.
35. Olesen JB, Gislason GH, Torp-Pedersen C, Lip GY. Atrial fibrillation and vascular disease-a bad combination. Clin Cardiol 2012;35(Suppl 1):15-20.
36. Kume O, Takahashi N, Wakisaka O, Nagano-Torigoe Y, Teshima Y, Nakagawa M et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011;8:278-85.
37. Zhou L, Azfer A, Niu J, Graham S, Choudhury M, Adamski FM et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 2006;98:1177-85.
38. Aimé-Sempé C, Folliguet T, Rücker-Martin C, Krajewska M, Krajewska S, Heimburger M et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34:1577-86.